BRITISH JOURNAL OF HAEMATOLOGY

Scope & Guideline

Pioneering Insights in Blood Disorders and Treatments

Introduction

Welcome to your portal for understanding BRITISH JOURNAL OF HAEMATOLOGY, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0007-1048
PublisherWILEY
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1955 to 2024
AbbreviationBRIT J HAEMATOL / Br. J. Haematol.
Frequency23 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The British Journal of Haematology aims to publish high-quality research that enhances the understanding and treatment of blood disorders, including various leukaemias, lymphomas, myelomas, and other haematological conditions. The journal encompasses a wide range of topics from basic research to clinical applications, providing an essential platform for disseminating new findings and therapeutic strategies.
  1. Clinical Trials and Treatment Efficacy:
    The journal frequently publishes results from clinical trials and observational studies that assess the efficacy and safety of new treatments for haematological malignancies, including novel agents like CAR T-cell therapies, targeted therapies, and immunotherapies.
  2. Transfusion Medicine and Blood Disorders:
    Research on transfusion practices, complications, and management of blood disorders such as sickle cell disease, thalassaemia, and immune thrombocytopenia is a core focus area, addressing both clinical and logistical aspects of transfusion medicine.
  3. Molecular and Genetic Insights:
    The journal emphasizes studies that explore the molecular and genetic basis of haematological diseases, including the impact of specific mutations on prognosis and treatment response, integrating genomics with clinical outcomes.
  4. Patient-Centered Outcomes:
    There is a strong emphasis on patient-reported outcomes and quality of life assessments in patients with haematological conditions, highlighting the importance of treatment impact on patients' daily lives.
  5. Guidelines and Best Practices:
    The journal serves as a platform for disseminating guidelines and consensus statements from leading haematology societies, ensuring that practitioners have access to the latest recommendations for diagnosis and management.
The British Journal of Haematology is at the forefront of emerging trends in haematology research, reflecting advancements in technology, therapy, and patient care. Recent publications highlight several key themes that are gaining traction within the field.
  1. Novel Immunotherapies and CAR T-Cell Therapies:
    There is a growing body of research focused on innovative immunotherapies, particularly CAR T-cell therapies, which are being extensively studied for their efficacy in treating various haematological malignancies.
  2. Real-World Data and Observational Studies:
    An increasing number of publications emphasize the importance of real-world evidence and observational studies, providing insights into treatment effectiveness and patient outcomes in everyday clinical settings.
  3. Genomic and Precision Medicine:
    Research into genomic profiling and precision medicine is on the rise, with studies exploring how genetic mutations and biomarkers can inform tailored treatment approaches for individual patients.
  4. Impact of COVID-19 on Haematology Patients:
    The journal has seen a surge in studies assessing the impact of COVID-19 on patients with haematological conditions, including the effects on treatment protocols and patient outcomes.
  5. Patient-Centric Research and Quality of Life Studies:
    There is an emerging trend towards research that prioritizes patient perspectives, including quality of life assessments and patient-reported outcomes, recognizing the importance of holistic care in managing haematological diseases.

Declining or Waning

While the British Journal of Haematology continues to cover a broad range of topics, certain areas of research have seen a decline in focus over the years. This may reflect shifts in clinical priorities or the completion of research cycles in these domains.
  1. Traditional Chemotherapy Approaches:
    There has been a noticeable decline in publications focused solely on traditional chemotherapy regimens for haematological malignancies, as the field increasingly shifts towards targeted therapies and immunotherapies that promise improved outcomes.
  2. Longitudinal Studies of Established Therapies:
    Research on the long-term outcomes of established therapies such as older chemotherapeutic agents has decreased, likely due to the emergence of new treatment modalities that attract more research interest.
  3. Generalized Studies Without Specific Focus:
    There appears to be less emphasis on broad, generalized studies that do not target specific haematological conditions or interventions, as the field gravitates towards more precise and targeted research.
  4. Classic Transfusion Practices:
    Although transfusion medicine remains a significant area of focus, the exploration of classic transfusion practices is waning, with more attention being given to innovative transfusion strategies and technologies.
  5. Historical Perspectives on Haematology:
    Papers focusing on historical aspects of haematology or retrospective analyses of outdated treatments are becoming less common, indicating a shift towards contemporary research that addresses current challenges.

Similar Journals

Blood Cancer Journal

Championing accessible research for global impact.
Publisher: SPRINGERNATUREISSN: 2044-5385Frequency: 1 issue/year

Blood Cancer Journal, published by SPRINGERNATURE, is a leading open-access journal that has been at the forefront of hematology and oncology research since its inception in 2011. With an impressive impact factor and a commitment to disseminating high-quality research, it holds a prestigious Q1 ranking in both hematology and oncology categories as of 2023. The journal is dedicated to publishing innovative studies, comprehensive reviews, and insightful commentaries that advance our understanding of blood cancers, making it an essential resource for researchers, healthcare professionals, and students in the field. Its open-access model ensures that groundbreaking research is accessible to a global audience, promoting collaborative efforts to enhance treatment methodologies and patient outcomes. With a strong reputation illustrated by its Scopus rankings—8th in hematology and 30th in oncology—Blood Cancer Journal exemplifies excellence and leadership in the ever-evolving landscape of cancer research.

Journal of Hematology

Empowering Research, Transforming Lives
Publisher: ELMER PRESS INCISSN: 1927-1212Frequency: 4 issues/year

The Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.

Turkish Journal of Hematology

Empowering the global hematology community through open access.
Publisher: GALENOS PUBL HOUSEISSN: 1300-7777Frequency: 4 issues/year

Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.

Lancet Haematology

Transforming the future of hematology, one study at a time.
Publisher: ELSEVIER SCI LTDISSN: 2352-3026Frequency: 12 issues/year

Lancet Haematology, published by Elsevier Science Ltd in the United Kingdom, is a premier peer-reviewed journal dedicated to advancing the field of hematology. With an impressive impact factor and listed in the Q1 category in hematology for 2023, this journal ranks #4 out of 137 in the Scopus database, boasting a 97th percentile indicating its influential role in disseminating high-quality research. Since its establishment in 2014, Lancet Haematology has provided a vital platform for researchers and clinicians to share groundbreaking studies, innovative treatment approaches, and novel therapeutic discoveries relevant to various hematological disorders. The journal does not operate under an open access model, but it offers multiple access options to facilitate engagement with its content. By bridging clinical practice and cutting-edge research, Lancet Haematology aims to foster the advancement of knowledge and improve patient outcomes in hematology, making it an essential read for professionals, researchers, and students alike.

Experimental Hematology & Oncology

Driving Progress in Blood Health and Cancer Solutions
Publisher: BMCISSN: Frequency: 1 issue/year

Experimental Hematology & Oncology is a premier journal published by BMC, dedicated to advancing knowledge in the fields of hematology, oncology, and cancer research. Since its inception in 2012, this Open Access journal has emerged as a vital resource for researchers and healthcare professionals, fostering the dissemination of high-quality research that enhances our understanding of blood disorders and malignancies. With impressive rankings in Quarters 1 of key categories including Cancer Research, Hematology, and Oncology, it holds significant prestige, evidenced by its Scopus rankings: #42/404 in Medicine (Oncology) and #17/137 in Medicine (Hematology). The journal aims to publish cutting-edge studies, reviews, and perspectives that contribute to the evolution of therapeutic strategies and innovative treatment modalities. Researchers and practitioners alike will find this journal indispensable for staying at the forefront of breakthroughs in hematological and oncological research.

LEUKEMIA

Championing Excellence in Cancer Research
Publisher: SPRINGERNATUREISSN: 0887-6924Frequency: 12 issues/year

LEUKEMIA, published by SpringerNature, is a premier journal in the field of hematology and oncology, with ISSN 0887-6924 and E-ISSN 1476-5551. Established in 1987, this esteemed publication serves as a critical platform for disseminating groundbreaking research and comprehensive reviews on the pathophysiology, diagnosis, and treatment of leukemia and related hematological disorders. With a distinguished impact, it holds a top-tier status in several categories, including Q1 rankings in Anesthesiology and Pain Medicine, Cancer Research, Hematology, and Oncology for 2023. The journal is globally recognized for its rigorous peer-review process and is highly regarded among academia, evidenced by its impressive Scopus rankings—7th in Hematology and 24th in Oncology. Researchers, clinicians, and students alike will benefit from the rich content that this journal offers, making it an invaluable resource in the fight against leukemia. The main objective of LEUKEMIA is to advance knowledge and encourage further innovations within the field, ensuring that vital insights reach practitioners and researchers around the world.

Journal of Blood Medicine

Unlocking Potential: Transforming Knowledge into Practice in Blood Medicine
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-2736Frequency: 1 issue/year

The Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.

TRANSFUSION AND APHERESIS SCIENCE

Bridging Theory and Practice in Transfusion and Apheresis
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 1473-0502Frequency: 6 issues/year

TRANSFUSION AND APHERESIS SCIENCE, published by Pergamon-Elsevier Science Ltd, serves as a pivotal platform for researchers and practitioners in the fields of hematology, transfusion medicine, and apheresis. With an ISSN of 1473-0502 and an E-ISSN of 1878-1683, this peer-reviewed journal boasts a respectable Q3 ranking in the Hematology category as of 2023, positioning it within the 45th percentile among its counterparts. Operating from the United Kingdom, it provides comprehensive insights into the latest advancements and methodologies in transfusion practices and apheresis technology, crucial for enhancing patient care and therapeutic strategies. The journal's scope, covering key developments from 1996 to 2024, allows for a deep exploration of historical and emerging trends within the discipline. Moreover, its open access options facilitate widespread dissemination of research findings, fostering collaboration and innovation in the scientific community. For those dedicated to advancing knowledge in hematology, TRANSFUSION AND APHERESIS SCIENCE represents an essential resource, bridging theory and practice in this vital area of healthcare.

Blood Cancer Discovery

Driving Collaborative Efforts for Better Patient Outcomes
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2643-3230Frequency: 6 issues/year

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

Cancer Discovery

Fostering Dialogue to Revolutionize Cancer Research
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2159-8274Frequency: 12 issues/year

Cancer Discovery, published by the American Association for Cancer Research, stands as a vital resource in the oncological research community, renowned for its commitment to disseminating groundbreaking studies and innovative findings in cancer biology, prevention, diagnostics, and treatment. With a significant impact factor reflecting its esteemed position, this journal facilitates open discussions and collaborations, striving to bridge the gap between experimental and clinical research. The journal, which has been active since 2011, is classified as a Q1 publication in 2023, underscoring its influence and authority in the realm of Oncology. By providing a platform for rigorous peer-reviewed articles, Cancer Discovery aims to advance our understanding of cancer and enhance therapeutic strategies, making it an indispensable tool for researchers, professionals, and students eager to stay at the forefront of cancer research.